AOD-9604 and hGH Fragment 176-191: Structure, β3-Adrenergic Pathway Mechanism, and the 16-Dalton Identity Problem — A 2026 Research Guide

AOD-9604 occupies an unusual position in the research peptide market. It is not a growth hormone secretagogue, not a GHRH analog, and not a growth hormone mimetic in the classical sense — it is a 16-residue excerpt of the growth hormone molecule itself, engineered in the 1990s at Monash University on the hypothesis that the metabolic and the somatogenic domains of hGH could be separated. It ran through a full clinical development program, was discontinued, was reclassified twice by the FDA in the space of a year, and is now sold almost everywhere as a research compound under two names for two molecules that differ by a single oxygen atom. That last detail is the analytical story, and it is the reason this compound deserves a careful sourcing conversation rather than a price comparison. This guide covers the molecular profile, the receptor-level mechanism, the published preclinical record, the regulatory history, and what a certificate of analysis on this peptide actually has to demonstrate.

The information below describes in-vitro and preclinical laboratory research only. It is not medical guidance, and none of the findings described here establish safety or efficacy in humans.

Section 1 — Molecular Profile

AOD-9604 is a synthetic hexadecapeptide corresponding to residues 176–191 of the C-terminus of human growth hormone, with a single engineered substitution: the native phenylalanine at the N-terminal position is replaced by tyrosine. The tyrosine was introduced to permit radioiodination for tracer studies, and it is the only structural difference between AOD-9604 and the native fragment.

Key identifiers used in the literature and on analytical documentation:

AOD-9604 (tyrosine-modified analog)

• Compound name: AOD-9604; AOD9604; Tyr-hGH 176-191
• CAS number: 221231-10-3
• Molecular formula: C78H123N23O23S2
• Molecular weight: approximately 1,815.1 Da
• Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF)
• Structure class: cyclic hexadecapeptide; intramolecular disulfide bridge between Cys7 and Cys14

hGH Fragment 176-191 (native, unmodified)

• Compound name: hGH Frag 176-191; HGH Fragment 176–191; growth hormone lipolytic fragment
• CAS number: 66004-57-7
• Molecular formula: C78H123N23O22S2
• Molecular weight: approximately 1,799.1 Da
• Sequence: Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (FLRIVQCRSVEGSCGF)

The two molecules are not interchangeable, and they are not the same product, but the entire structural difference between them is one hydroxyl group on residue 1 — a mass difference of exactly 16 daltons. Hold that number; it is the central analytical problem of this compound and it returns in Section 6.

Two composition details drive handling. First, the disulfide bridge between Cys7 and Cys14 is a structural requirement, not an incidental feature: the peptide’s defined conformation depends on it. Reducing conditions convert the cyclic form to the linear dithiol, a 2-dalton shift, and intermolecular oxidation produces disulfide-linked dimers at roughly twice the monomer mass. Second, the sequence carries two arginines and a glutamate, so lyophilized material carries a counterion load — commonly acetate or trifluoroacetate depending on purification route — which means gross vial weight and net peptide content are different figures. Standard practice is storage of lyophilized material at −20 °C or below, desiccated, with reconstituted stock aliquoted to avoid freeze-thaw cycling that can promote disulfide scrambling.

Section 2 — Mechanism

All activity described here is at the receptor and pathway level, in defined experimental systems.

The design hypothesis. Intact human growth hormone signals through the growth hormone receptor, a class I cytokine receptor that activates JAK2 and the STAT5 pathway, driving hepatic IGF-1 transcription — the somatogenic arm of GH biology. Work at Monash University in the 1990s pursued the hypothesis that hGH’s actions on adipose tissue lipid metabolism were carried by a discrete C-terminal domain and could be separated from the JAK2/STAT5/IGF-1 axis. AOD-9604 is the synthetic expression of that hypothesis: the C-terminal 176–191 region, isolated from the rest of the molecule.

The β3-adrenergic pathway. The mechanism most consistently reported in the preclinical literature runs through β3-adrenergic receptor signalling in adipocytes rather than through the growth hormone receptor. The canonical in-vitro cascade is well characterized independently of this compound: β3-AR is a Gs-coupled GPCR expressed on white and brown adipocytes; activation raises intracellular cAMP through adenylyl cyclase; cAMP activates protein kinase A; PKA phosphorylates hormone-sensitive lipase and perilipin-1, which together license triglyceride hydrolysis at the lipid droplet surface. Reported in-vitro observations with AOD-9604 in differentiated adipocyte culture describe elevated cAMP and increased HSL phosphorylation — readouts consistent with engagement of that pathway.

The strongest published evidence for β3-AR involvement is genetic rather than pharmacological. Heffernan and colleagues (2001, Endocrinology) reported that chronic administration of hGH or AOD9604 in β3-AR knock-out mice failed to reproduce the changes in adipose tissue lipid handling observed in wild-type controls, while wild-type responses correlated with increased β3-AR transcript expression. The same work reported that in acute experiments the compound still altered energy expenditure and fat oxidation in β3-AR knock-out animals — which is a genuinely unresolved point, and it says that the pathway picture is incomplete rather than settled. A direct high-affinity binding interaction between this peptide and β3-AR has not been cleanly demonstrated; the receptor-level mechanism remains an area of active inference.

Dissociation from the IGF-1 axis. The consistent finding across the preclinical and clinical pharmacology literature is that AOD-9604 does not raise serum IGF-1 and does not reproduce the carbohydrate-metabolism effects associated with intact hGH. Ng and colleagues (2000, Hormone Research) reported that chronic treatment in obese Zucker rats, unlike chronic intact hGH, showed no adverse effect on insulin sensitivity under euglycemic clamp. Stier and colleagues (2013) reported no effect on serum IGF-1 across the human study program. Whatever this fragment does, the evidence indicates it does not do it by activating the growth hormone receptor — which is the whole point of the molecule and the reason it remains mechanistically interesting.

Chondrocyte and matrix signalling. A separate and more recent line of preclinical work has examined the peptide in cartilage models. Reported in-vitro observations in isolated chondrocytes describe increased proteoglycan and type II collagen production and altered matrix metalloproteinase activity, with parallel work describing effects on differentiation of adipose-derived mesenchymal stem cells. These are pathways the compound has been studied for; the mechanistic detail here is thinner than the metabolic literature and should be read as early-stage.

Throughout the record these are mechanisms AOD-9604 has been researched for — β3-adrenergic/cAMP/PKA/HSL pathway engagement in adipocyte culture, dissociation from GHR–JAK2–STAT5–IGF-1 signalling, and matrix protein expression in chondrocyte models — not demonstrated clinical effects.

Section 3 — Preclinical and In-Vitro Research Data

Rodent metabolic studies. Ng et al. (2000) treated obese Zucker rats orally for 19 days and reported reduced body weight gain relative to control alongside increased lipolytic activity measured in adipose tissue, with no euglycemic-clamp evidence of impaired insulin sensitivity. Heffernan et al. published two 2001 papers: one in the International Journal of Obesity reporting increased fat oxidation in obese mice following chronic treatment with hGH or the modified C-terminal fragment, and one in Endocrinology establishing the β3-AR dependence described above through knock-out comparison. These three papers are the load-bearing preclinical citations for the metabolic mechanism, and all three are rodent studies.

Adipocyte culture work. In-vitro work in differentiated adipocytes has reported elevated cAMP concentrations and increased hormone-sensitive lipase phosphorylation on exposure to the peptide — the expected proximal readouts if the β3-AR/Gs/PKA axis is being engaged. It is worth being precise about what this establishes: pathway engagement in a dish, in a cell line, at concentrations chosen by the experimenter. It is not an organismal result and it is not a human result.

Cartilage models. Kwon and Park (2015, Annals of Clinical and Laboratory Science) reported a collagenase-induced knee osteoarthritis model in 32 New Zealand white rabbits, comparing weekly intra-articular saline, hyaluronic acid, AOD9604, and AOD9604 combined with HA. Gross morphological and histopathological scores were reported as significantly worse in the saline control group than in treated groups, with the combination group showing the shortest lameness period. This is a small-animal model study and should be read as such.

Human study program and its limits. Between 2001 and 2006, six randomized double-blind placebo-controlled trials enrolling 893 adults were conducted, summarized by Stier and colleagues in the Journal of Endocrinology and Metabolism in 2013. The relevant findings for a research-context reading are mechanistic and safety-oriented: no effect on serum IGF-1, and oral glucose tolerance testing that did not show the carbohydrate-metabolism signal associated with intact hGH. The development program was not carried through to drug approval, and the compound was subsequently repositioned as a nutraceutical ingredient rather than a pharmaceutical. No efficacy conclusion is drawn here, none should be inferred, and nothing in that clinical record applies to research-grade lyophilized material, which is a different product supplied under a different regulatory status for a different purpose.

Two limitations deserve plain statement. First, the mechanistic literature is thin relative to the compound’s market visibility — the core metabolic pharmacology rests on a small number of papers, most of them more than two decades old, and the receptor-level interaction has never been resolved structurally. Second, the modern in-vitro adipocyte and chondrocyte literature is scattered across low-visibility publications and vendor-adjacent summaries; researchers should trace claims back to primary sources rather than to secondary aggregation, because in this compound’s case the aggregation frequently overstates what the primary papers reported.

Section 4 — Published Literature

The following are real, published papers anchoring the AOD-9604 record. Researchers should consult the primary sources directly.

• Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R (2000). “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.” Hormone Research 53(6):274–278. PMID 11146367. DOI 10.1159/000053183. The originating metabolic characterization in obese Zucker rats.
• Heffernan MA, Thorburn AW, Fam B, et al. (2001). “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.” International Journal of Obesity and Related Metabolic Disorders 25(10):1442–1449. PMID 11673763.
• Heffernan M, Summers RJ, Thorburn A, et al. (2001). “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice.” Endocrinology 142(12):5182–5189. PMID 11713213. The β3-adrenergic receptor dependence study.
• Stier H, Vos E, Kenley D (2013). “Safety and tolerability of the hexadecapeptide AOD9604 in humans.” Journal of Endocrinology and Metabolism 3(1-2):7–15. Pooled safety analysis of six randomized placebo-controlled trials, n=893.
• Kwon DR, Park GY (2015). “Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model.” Annals of Clinical and Laboratory Science 45(4):426–432. PMID 26124272.
• Moré MI, Kenley D, et al. “Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health.” Journal of Endocrinology and Metabolism. Post-development repositioning literature.
• Ng FM, Bornstein J (1978 onward series). Early work at Monash on the lipolytic activity of hGH C-terminal fragments, which established the domain hypothesis the later analog was built on.

Background reading on the pathway itself, independent of this compound, is worth pairing with the above — the β3-adrenergic receptor lipolysis literature (including work on β3-AR regulation of human brown and beige adipocyte lipolysis published in 2021, PMID 34100382, and on β3-AR downregulation in obesity, PMID 34847077) gives the assay context that the AOD-9604 papers assume.

Section 5 — Research Applications

In laboratory settings this compound appears principally in adipocyte and adipose-tissue metabolic pathway work. Reported in-vitro applications include cAMP accumulation assays in differentiated 3T3-L1 or primary adipocyte culture; western blot quantification of hormone-sensitive lipase and perilipin-1 phosphorylation state; glycerol and non-esterified fatty acid release assays as functional lipolysis readouts; qPCR panels for β3-AR transcript expression; comparative work against β3-AR agonists such as CL-316,243 and against intact hGH as a GHR-active comparator; and — in the cartilage literature — proteoglycan and type II collagen expression assays in isolated chondrocytes.

Assay-design variables worth attention. Because the proposed mechanism converges on cAMP, phosphodiesterase inhibitor presence in the buffer materially changes the dynamic range of any cAMP readout and must be reported rather than assumed. Because β3-AR expression differs sharply between species and between cell lines — murine 3T3-L1 adipocytes and primary human subcutaneous adipocytes are not equivalent systems for this receptor, a point established in the human β3-AR literature going back to the 1990s — cross-model comparisons of apparent potency are not meaningful without stating the system. Because the peptide’s structure depends on an intramolecular disulfide, reducing agents in the assay buffer are a variable that can silently alter what is actually being tested. And because the compound has been studied by oral, intravenous, and intra-articular routes in different published models, “the AOD-9604 literature” is not one literature — the route and model should be carried forward when citing.

Section 6 — How to Evaluate a Source

This compound presents the most under-discussed identity problem in the research peptide market, and it comes down to that 16-dalton figure from Section 1.

AOD-9604 (approximately 1,815.1 Da) and hGH fragment 176-191 (approximately 1,799.1 Da) differ by one oxygen atom — the hydroxyl distinguishing tyrosine from phenylalanine at position 1. Sixteen daltons is also, precisely, the mass shift produced by oxidation of a single residue. A vendor shipping native hGH fragment 176-191 in a vial labelled AOD-9604 is shipping material whose parent mass sits 16 daltons low; a lot of genuine AOD-9604 carrying oxidation is material whose satellite peak sits 16 daltons high. On a mass number alone, those two situations are not distinguishable from each other, and neither is distinguishable from a correctly identified lot of the other compound. The two peptides are also frequently synthesized and filled in the same facilities, and the market uses the two names loosely enough that some listings present them as synonyms — which they are not.

What resolves it: an LC-MS identity determination that reports observed mass and the chromatographic method, ideally with MS/MS fragmentation or comparison against a characterized reference standard. A single number on a PDF does not settle which of the two peptides is in the vial.

The disulfide adds a second, independent question. The defined structure is the cyclic Cys7–Cys14 form. The reduced linear form sits 2 daltons higher, and intermolecular disulfide dimers sit near 3,630 Da. Both are real failure modes for a cysteine-containing peptide, both are visible on a competent reversed-phase trace and mass spectrum, and neither is visible on a purity percentage stated without supporting data.

What the analytical package needs to show:

• Purity by HPLC, with a stated percentage and the chromatogram. For a 16-residue disulfide-cyclized peptide the relevant impurity classes are deletion sequences, the reduced linear form, disulfide-linked dimers, and oxidation products. A bare “≥99%” with no trace does not identify which impurities are present.
• Identity by LC-MS, with an observed mass reported against the expected value — approximately 1,815.1 Da for AOD-9604, approximately 1,799.1 Da for hGH fragment 176-191 — and enough method detail to establish that the 16-dalton question was actually asked.
• Endotoxin by USP <85> LAL, with an actual figure rather than a “meets specification” checkbox.
• Heavy metals by ICP-MS.
• Net peptide content and counterion, disclosed. Acetate and trifluoroacetate carry different mass burdens on an 1,815 Da peptide, and residual TFA is biologically active in some cell assays at concentrations that survive lyophilization.
• Lot-specificity. The COA must correspond to the exact batch shipped, be dated, and name the accredited laboratory that performed the testing. A COA reused across lots is a marketing document.

Market pricing context: research-grade AOD-9604 at the 5 mg scale is commonly listed in roughly the $20–$45 range at the low end and roughly $45–$90 at vendors publishing independent third-party testing, with 10 mg presentations and bulk pricing scaling below that per milligram. A 16-residue peptide with one disulfide bridge is a routine solid-phase synthesis with a straightforward oxidative folding step, so the spread across that range reflects testing, documentation, and margin far more than synthesis difficulty. Price is a weak signal on this compound. The identity test is the argument.

Regulatory history worth knowing. In September 2023 the FDA placed AOD-9604 in Category 2 of the interim 503A bulk drug substances list — substances nominated with sufficient supporting information but raising significant safety concerns, with the agency citing immunogenicity, impurities, and limited human data. In September 2024 the FDA removed AOD-9604 from Category 2, along with CJC-1295, ipamorelin acetate, thymosin alpha-1, and selank acetate, on withdrawal of the underlying nominations. AOD-9604 was not among the seven substances reviewed at the July 2026 Pharmacy Compounding Advisory Committee meeting, and it is not among the five scheduled for the PCAC review due before the end of February 2027. Separately, growth hormone fragments including AOD-9604 and hGH 176-191 are prohibited under the World Anti-Doping Agency’s S2 peptide hormones category, which is relevant to any laboratory working in sports-science contexts. None of this changes the status of material genuinely supplied for laboratory work — but it does mean documentation and labelling discipline are not optional in 2026.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

On a compound where two commercially distinct peptides sit sixteen daltons apart, and where sixteen daltons is also the signature of ordinary oxidation, the identity determination is not a formality appended to a purity number. It is the measurement that decides which molecule is in the vial. A published mass spectrum and chromatogram on the actual lot settles in one document what no amount of label copy can.

Founding batches are documented end to end, with full analytical data files available per lot. You can review current documentation in the COA library, read the underlying methodology on the verification standard page, see the AOD-9604 listing, or browse the full catalog in the shop.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.